Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Rezolute, Inc. RZLT
$4.09
▲ +5.68%
(+$0.22)
🔥 High Short Interest
Open
$3.94
Prev Close
$3.87
Day Range
$3.90 – $4.22
52W Range
$1.07 – $11.46
Market Cap
$374.34M
Beta
0.62
EPS (TTM)
$-0.75
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-12-23 |
| Shares Out. | 96,730,000 |
| Website | rezolutebio.com/ ↗ |
| Phone | 16502064507 |
| Employees | 58 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$20.5M |
| Free Cash Flow | -$64.6M |
| Total Assets | $112.8M |
| Total Liabilities | $12.2M |
| Equity | $100.7M |
About Rezolute, Inc.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Rezolute, Inc. is a publicly traded company under the ticker symbol RZLT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-11-01)